Literature DB >> 17333308

Comparative QSAR studies on peptide deformylase inhibitors.

Ji Young Lee1, Munikumar Reddy Doddareddy, Yong Seo Cho, Hyunah Choo, Hun Yeong Koh, Jae-Hoon Kang, Kyoung Tai No, Ae Nim Pae.   

Abstract

Comparative quantitative structure-activity relationship (QSAR) analyses of peptide deformylase (PDF) inhibitors were performed with a series of previously published (British Biotech Pharmaceuticals, Oxford, UK) reverse hydroxamate derivatives having antibacterial activity against Escherichia coli PDF, using 2D and 3D QSAR methods, comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), and hologram QSAR (HQSAR). Statistically reliable models with good predictive power were generated from all three methods (CoMFA r (2) = 0.957, q (2) = 0.569; CoMSIA r (2) = 0.924, q (2) = 0.520; HQSAR r (2) = 0.860, q (2) = 0.578). The predictive capability of these models was validated by a set of compounds that were not included in the training set. The models based on CoMFA and CoMSIA gave satisfactory predictive r (2) values of 0.687 and 0.505, respectively. The model derived from the HQSAR method showed a low predictability of 0.178 for the test set. In this study, 3D prediction models showed better predictive power than 2D models for the test set. This might be because 3D information is more important in the case of datasets containing compounds with similar skeletons. Superimposition of CoMFA contour maps in the active site of the PDF crystal structure showed a meaningful correlation between receptor-ligand binding and biological activity. The final QSAR models, along with information gathered from 3D contour and 2D contribution maps, could be useful for the design of novel active inhibitors of PDF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333308     DOI: 10.1007/s00894-007-0175-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   2.172


  33 in total

Review 1.  Antibacterials: are the new entries enough to deal with the emerging resistance problems?

Authors:  Christine T Barrett; John F Barrett
Journal:  Curr Opin Biotechnol       Date:  2003-12       Impact factor: 9.740

2.  In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.

Authors:  Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Peptide deformylase inhibitors with activity against respiratory tract pathogens.

Authors:  Stephen P East; R Paul Beckett; Daniel C Brookings; John M Clements; Sheila Doel; Kenneth Keavey; Gilles Pain; Helen K Smith; Wayne Thomas; Alison J Thompson; Richard S Todd; Mark Whittaker
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

4.  Actinonin: an antibiotic substance produced by an actinomycete.

Authors:  J J GORDON; B K KELLY; G A MILLER
Journal:  Nature       Date:  1962-08-18       Impact factor: 49.962

5.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Authors:  R D Cramer; D E Patterson; J D Bunce
Journal:  J Am Chem Soc       Date:  1988-08-01       Impact factor: 15.419

6.  Peptide deformylase as an emerging target for antiparasitic agents.

Authors:  C Giglione; T Meinnel
Journal:  Expert Opin Ther Targets       Date:  2001-02       Impact factor: 6.902

7.  Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor.

Authors:  W Tong; D R Lowis; R Perkins; Y Chen; W J Welsh; D W Goddette; T W Heritage; D M Sheehan
Journal:  J Chem Inf Comput Sci       Date:  1998 Jul-Aug

8.  Deformylation and protein biosynthesis.

Authors:  D M Livingston; P Leder
Journal:  Biochemistry       Date:  1969-01       Impact factor: 3.162

9.  Design and synthesis of substrate analogue inhibitors of peptide deformylase.

Authors:  T Meinnel; L Patiny; S Ragusa; S Blanquet
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

10.  Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.